Cite
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
MLA
Vardeny, Orly, et al. “Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF Trial.” European Journal of Heart Failure, vol. 18, no. 10, Oct. 2016, pp. 1228–34. EBSCOhost, https://doi.org/10.1002/ejhf.580.
APA
Vardeny, O., Claggett, B., Packer, M., Zile, M. R., Rouleau, J., Swedberg, K., Teerlink, J. R., Desai, A. S., Lefkowitz, M., Shi, V., McMurray, J. J. V., Solomon, S. D., & Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. (2016). Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 18(10), 1228–1234. https://doi.org/10.1002/ejhf.580
Chicago
Vardeny, Orly, Brian Claggett, Milton Packer, Michael R. Zile, Jean Rouleau, Karl Swedberg, John R. Teerlink, et al. 2016. “Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF Trial.” European Journal of Heart Failure 18 (10): 1228–34. doi:10.1002/ejhf.580.